## **Supplementary Figures**



Supplementary Figure 1. <sup>1</sup>H NMR of 2PMPA-PEG-N<sub>3</sub> (compound 2) in D<sub>2</sub>O



Supplementary Figure 2. ESI-MS spectra of 2PMPA-PEG-N<sub>3</sub> (compound 2)





Supplementary Figure 4. <sup>1</sup>H NMR of D-2PMPA (compound 5) in D<sub>2</sub>O



**Supplementary Figure 5**. HPLC trace of D-2PMPA (compound **5**) at 210nm showing a purity >99%

Voyager Spec #1=>BC=>NR(5.00)[BP = 5051.9, 2261]



Supplementary Figure 6. MALDI-ToF spectra of D-2PMPA (compound 5)



Supplementary Figure 8. <sup>1</sup>H NMR of compound 7 in DMSO-d6



Supplementary Figure 9. <sup>1</sup>H NMR of compound 8 in DMSO-d6



Supplementary Figure 10. <sup>1</sup>H NMR of Cy5-D-2PMPA (compound 9) in DMSO-d6



**Supplementary Figure 11**. HPLC chromatogram of Cy5-D-2PMPA (compound **9**) showing greater than 99% purity



Supplementary Figure 12. Anti-inflammatory effect of D-2PMPA on LPS-treated glial cultures. D-2PMPA downregulates pro-inflammatory markers A. iNOS and B. TNF $\alpha$  and causes a trend increase in C. NR2A. Significantly different from control at P<0.001(\*\*\*). Significantly different from LPS at P<0.05(+).